Together with our data, these observations support a critical role for ACTN1 in conferring chemoresistance in tumor cells, and its targeting holds potential to re-sensitize tumors to taxane-based chemotherapeutics agent, which are still standard care of treatment regimens for TNBC patients (Mustacchi and De Laurentiis, 2015). Here, ACTN1 is linked to neoplasm.